NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/21/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization746.89 mln
Float5.13 mln
Earnings Date08/13/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
168
Transformational upside
Relative Strength
98
/ 100
Top performer
Debt / Equity
0.00
Debt-free
ROE
-23.37
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Bright Minds Biosciences is a US-based biotech company focused on developing new treatments for serious neurological and psychiatric conditions, including epilepsy, developmental brain disorders, and Prader Willi Syndrome. The company has several drug candidates at various stages of clinical testing, with its lead program BMB-101 currently in Phase 2 trials. Founded in 2017 and based in New York, Bright Minds works with partners such as Firefly Neuroscience to support its ongoing research.
